Meghalaya Magazine

Anaplastic Astrocytoma Clinical Trials Pipeline Analysis: 15+ Companies are working to improve the Treatment of Space

 Breaking News
  • No posts were found

Anaplastic Astrocytoma Clinical Trials Pipeline Analysis: 15+ Companies are working to improve the Treatment of Space

February 28
23:01 2023
Anaplastic Astrocytoma Clinical Trials Pipeline Analysis: 15+ Companies are working to improve the Treatment of Space

DelveInsight’s, “Anaplastic Astrocytoma Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Anaplastic Astrocytoma pipeline landscape. It covers the Anaplastic Astrocytoma pipeline drug profiles, including Anaplastic Astrocytoma clinical trials and nonclinical stage products. It also covers the Anaplastic Astrocytoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Anaplastic Astrocytoma Emerging drugs, the Anaplastic Astrocytoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Anaplastic Astrocytoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Anaplastic Astrocytoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Anaplastic Astrocytoma clinical trials studies, Anaplastic Astrocytoma NDA approvals (if any), and product development activities comprising the technology, Anaplastic Astrocytoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Anaplastic Astrocytoma Pipeline Report

 

  • Over 15+ Anaplastic Astrocytoma companies are evaluating 15+ Anaplastic Astrocytoma pipeline therapies in various stages of development, and their anticipated acceptance in the Anaplastic Astrocytoma market would significantly increase market revenue.

 

  • The leading Anaplastic Astrocytoma Companies includes Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.

 

  • Promising Anaplastic Astrocytoma Pipeline Therapies includes Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, Bononophenylalanine (BPA)-based BNCT, leflunomide, LS11 (talaporfin sodium), Temozolomide, Semustine, CC-90010, and others.

 

  • The Anaplastic Astrocytoma companies and academics that are working to assess challenges and seek opportunities that could influence Anaplastic Astrocytoma R&D. The Anaplastic Astrocytoma pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the Me Anaplastic Astrocytoma Pipeline treatment landscape of the report, click here @ Anaplastic Astrocytoma Pipeline Outlook

 

Anaplastic Astrocytoma Overview

Anaplastic Astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. Astrocytes and similar cells form tissue that surrounds and protects other nerve cells found within the brain and spinal cord. Collectively, these cells are known as glial cells and the tissue they form is known as glial tissue. Tumors that arise from glial tissue, including astrocytomas, are collectively referred to as gliomas. The symptoms of Anaplastic Astrocytomas vary depending upon the specific location and size of the tumor. The specific cause of this tumor is unknown.

 

Recent Developmental Activities in the Anaplastic Astrocytoma Treatment Landscape

 

  • In October 2021, Cothera Bioscience Inc. and Adastra Pharmaceuticals Inc., announced a definitive agreement under which Cothera has acquired zotiraciclib (ZTR).

 

For further information, refer to the detailed Anaplastic Astrocytoma Unmet Needs, Anaplastic Astrocytoma Market Drivers, and Anaplastic Astrocytoma Market Barriers, click here for Anaplastic Astrocytoma Ongoing Clinical Trial Analysis

 

Anaplastic Astrocytoma Emerging Drugs Profile

 

  • Eflornithine: Orbus Therapeutics

Eflornithine, also known as α-diflurormethylornithine (DFMO), selectively targets and irreversibly inhibits ornithine decarboxylase (ODC), an enzyme essential for polyamine synthesis, and DNA and RNA function.  Unlike multi-targeted tyrosine kinase inhibitors on the market or in development, eflornithine targets only one specific enzyme, ODC. In animal studies, eflornithine has been shown to inhibit the growth of malignant tumors, including intra cerebral mid- and high-grade gliomas. Eflornithine administration has also been shown to potentiate the anti-tumor activity of other chemotherapy agents. In single-arm and controlled, randomized clinical trials, eflornithine oral solution increased survival in patients with both newly diagnosed and recurrent anaplastic glioma. The primary and reversible side effects of eflornithine were diarrhea and hearing impairment.

 

  • Zotiraciclib: Cothera Bioscience

Zotiraciclib is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9. In October 2021, Cothera Bioscience Inc. and Adastra Pharmaceuticals Inc., announced a definitive agreement under which Cothera has acquired zotiraciclib (ZTR).

 

Anaplastic Astrocytoma Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Anaplastic Astrocytoma. The companies which have their Anaplastic Astrocytoma drug candidates in the most advanced stage, i.e. phase III include, Orbus Therapeutics.

 

Request a sample and discover the recent advances in Anaplastic Astrocytoma Ongoing Clinical Trial Analysis and Medications, click here @ Anaplastic Astrocytoma Treatment Landscape

 

Scope of the Anaplastic Astrocytoma Pipeline Report

 

  • Coverage- Global

 

  • Anaplastic Astrocytoma Companies- Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.

 

  • Anaplastic Astrocytoma Pipeline Therapies- Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, Bononophenylalanine (BPA)-based BNCT, leflunomide, LS11 (talaporfin sodium), Temozolomide, Semustine, CC-90010, and others.

 

  • Anaplastic Astrocytoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Anaplastic Astrocytoma Market Drivers and Anaplastic Astrocytoma Market Barriers, click here @ Anaplastic Astrocytoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Anaplastic astrocytoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anaplastic astrocytoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Eflornithine: Orbus Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. GT-10: Geneos Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. CLX-ONC-643: Cellix Bio
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Anaplastic astrocytoma Key Companies
  21. Anaplastic astrocytoma Key Products
  22. Anaplastic astrocytoma- Unmet Needs
  23. Anaplastic astrocytoma- Market Drivers and Barriers
  24. Anaplastic astrocytoma- Future Perspectives and Conclusion
  25. Anaplastic astrocytoma Analyst Views
  26. Anaplastic astrocytoma Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Anaplastic Astrocytoma Mergers and acquisitions, Anaplastic Astrocytoma Licensing Activities @ Anaplastic Astrocytoma Emerging Drugs, and Recent Trends

 

 About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services